Repositioning Candidate Details
| Candidate ID: | R0180 |
| Source ID: | DB00630 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Alendronic acid |
| Synonyms: | |
| Molecular Formula: | C4H13NO7P2 |
| SMILES: | NCCCC(O)(P(O)(O)=O)P(O)(O)=O |
| Structure: |
|
| DrugBank Description: | Alendronic acid is a bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959]. It functions by preventing resorption of bone[FDA Label][A959]. |
| CAS Number: | 66376-36-1 |
| Molecular Weight: | 249.096 |
| DrugBank Indication: | Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label]. |
| DrugBank Pharmacology: | Alendronic acid tablets have a very low oral bioavialability[FDA Label][A176750]. After administration it distributes into soft tissue and bone or is excreted in the urine[FDA Label]. Alendronic acid does not undergo metabolism[FDA Label]. |
| DrugBank MoA: | Alendronic acid binds to bone hydroxyapatite[FDA Label]. Bone resorption causes local acidification, releasing alendronic acid which is that taken into osteoclasts by fluid-phase endocytosis[A959]. Endocytic vesicles are acidified, releasing alendronic acid to the cytosol of osteoclasts where they induce apoptosis[A959]. Inhibition of osteoclasts results in decreased bone resorption which is shown through decreased urinary calcium, deoxypyridinoline and cross-linked N-telopeptidases of type I collagen[FDA Label]. |
| Targets: | Farnesyl pyrophosphate synthase; Hydroxylapatite; Tyrosine-protein phosphatase non-receptor type 4; Receptor-type tyrosine-protein phosphatase S; Receptor-type tyrosine-protein phosphatase epsilon; V-type proton ATPase catalytic subunit A |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |